| Variable |
Time |
Group A (n=55) |
Group B (n=50) |
P-value |
| Weight (Kg) |
Baseline |
53 ± 13.5 |
53 ± 12.4 |
1 |
| 2 months |
55 ± 11.1 |
55 ± 12.0 |
0.81 |
| 4 months |
56 ± 11.8 |
57 ± 12.6 |
0.7 |
| 6 months |
57 ± 12.1 |
57 ± 12.1 |
0.7 |
| 12 months |
59 ± 11.2 |
60 ± 10.0 |
0.66 |
| Hemoglobin (g/dL) |
Baseline |
11.3 ± 1.7 |
12.0 ± 2.0 |
0.09 |
| 2 weeks |
11.8 ± 1.8 |
12.4 ± 2.0 |
0.17 |
| 2 months |
12.4 ± 1.8 |
12.9 ± 1.8 |
0.28 |
| 4 months |
12.8 ± 1.9 |
13.2 ± 2.0 |
0.39 |
| 6 months |
12.7 ± 2.1 |
13.5 ± 1.9 |
0.14 |
| 12 months |
13.4 ± 1.6 |
13.8 ± 1.8 |
0.41 |
| AST (IU/L)* |
Baseline |
22 (10 - 76) |
31 (2 - 108) |
0.13 |
| 2 weeks |
31 (10 - 537) |
43 (11 - 558) |
0.1 |
| 2 months |
31 (10 - 184) |
31 (10 - 172) |
0.85 |
| 4 months |
30 (10 - 142) |
29 (8 - 147) |
0.6 |
| 6 months |
33 (10 - 332) |
33 (8 - 92) |
0.83 |
| 12 months |
26 (11 - 108) |
27 (5 - 113) |
0.74 |
| ALT (IU/L)* |
Baseline |
28 (17 - 98) |
31 (16 - 74) |
0.27 |
| 2 weeks |
38 (10 - 272) |
38 (18 - 442) |
0.32 |
| 2 months |
34 (9 - 140) |
33 (18 - 185) |
0.79 |
| 4 months |
32 (15 - 136) |
29 (9 - 152) |
0.55 |
| 6 months |
37 (17 - 235) |
30 (12 - 146) |
0.12 |
| 12 months |
29 (10 - 88) |
27 (18 - 70) |
0.41 |
| ESR (mm/hr)* |
Baseline |
38 (9 - 134) |
35 (2 - 139) |
0.22 |
| 2 weeks |
30 (2 - 114) |
31 (2 - 138) |
0.29 |
| 2 months |
28 (2 - 117) |
25 (2 - 60) |
0.28 |
| 4 months |
22 (2 - 55) |
20 (2 - 44) |
0.48 |
| 6 months |
20 (2 - 78) |
20 (2 - 38) |
0.17 |
| 12 months |
16 (2-40) |
12 (4-42) |
0.06 |
|
| *-Variables summary statistics are presented as Median (Range). P values are from Wilcoxon Ranksum test. The rest of the variable summary statistics are mean ± SD. The P values are from GEE analysis. ESR: Erythrocyte sedimentation rate; AST: Aspartate amniotransferase; ALT: Alanine aminotransferase |
| Table 3: Laboratory and clinical parameters during follow-up. |
